Incidence and prevalence of axial spondyloarthritis: Methodologic challenges and gaps in the literature

Rhonda Bohn, Maureen Cooney, Atulya (Atul) Deodhar, Jeffrey R. Curtis, Amanda Golembesky

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective The incidence and prevalence of axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic (nr-)axSpA, have been investigated in multiple populations, though there is a paucity of population-level data. Here, we identify population-based studies in AS and nr-axSpA, and describe the methodologic challenges in conducting these, outlining potential reasons for disparate incidence and prevalence estimates. Methods PubMed and Embase were searched for population-based studies providing incidence and prevalence rates, published in English from 1 Jan 2000-30 Jun 2015. Extracted information included incidence/prevalence rates, geographical population, study design, data source, case definition, age/gender, and classification criteria used. Results Of 2,148 articles identified, 19, from 15 countries, fulfilled eligibility criteria. Incidence rates per 100,000 patient-years were reported in 4 AS studies and varied from 0.4 (Iceland) to 15.0 (Canada). Reported AS prevalence rates per 100,000 persons also showed considerable variation (16 studies: 6.5 [Japan] to 540.0 [Turkey]). Only 3 axSpA and no nr-axSpA prevalence rates were reported. Considerable variation was seen in the methodology used to estimate incidence and prevalence rates, e.g. screening method, study design, and classification criteria. Although the prevalence of AS is known to vary by HLA-B27 status, only 4 studies reported this genetic marker. Conclusion There is an unmet need for future studies to use consistent methodology, capture all relevant information (including HLA-B27 positivity), and investigate under-reported populations (e.g. nr-axSpA; southern hemisphere countries) to estimate the population burden of axSpA. Future studies should aim to address data gaps to provide accurate incidence/ prevalence estimates for the global axSpA population.

Original languageEnglish (US)
Pages (from-to)263-274
Number of pages12
JournalClinical and Experimental Rheumatology
Volume36
Issue number2
StatePublished - Jan 1 2018

Fingerprint

Ankylosing Spondylitis
Incidence
Population
HLA-B27 Antigen
Iceland
Information Storage and Retrieval
Turkey
Genetic Markers
PubMed
Canada
Japan
Cohort Studies
Cross-Sectional Studies

Keywords

  • Ankylosing spondylitis
  • Epidemiology
  • Incidence
  • Prevalence
  • Spondylarthropathies

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Incidence and prevalence of axial spondyloarthritis : Methodologic challenges and gaps in the literature. / Bohn, Rhonda; Cooney, Maureen; Deodhar, Atulya (Atul); Curtis, Jeffrey R.; Golembesky, Amanda.

In: Clinical and Experimental Rheumatology, Vol. 36, No. 2, 01.01.2018, p. 263-274.

Research output: Contribution to journalArticle

Bohn, Rhonda ; Cooney, Maureen ; Deodhar, Atulya (Atul) ; Curtis, Jeffrey R. ; Golembesky, Amanda. / Incidence and prevalence of axial spondyloarthritis : Methodologic challenges and gaps in the literature. In: Clinical and Experimental Rheumatology. 2018 ; Vol. 36, No. 2. pp. 263-274.
@article{d9cf0bee31524362a602c38f56778f44,
title = "Incidence and prevalence of axial spondyloarthritis: Methodologic challenges and gaps in the literature",
abstract = "Objective The incidence and prevalence of axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic (nr-)axSpA, have been investigated in multiple populations, though there is a paucity of population-level data. Here, we identify population-based studies in AS and nr-axSpA, and describe the methodologic challenges in conducting these, outlining potential reasons for disparate incidence and prevalence estimates. Methods PubMed and Embase were searched for population-based studies providing incidence and prevalence rates, published in English from 1 Jan 2000-30 Jun 2015. Extracted information included incidence/prevalence rates, geographical population, study design, data source, case definition, age/gender, and classification criteria used. Results Of 2,148 articles identified, 19, from 15 countries, fulfilled eligibility criteria. Incidence rates per 100,000 patient-years were reported in 4 AS studies and varied from 0.4 (Iceland) to 15.0 (Canada). Reported AS prevalence rates per 100,000 persons also showed considerable variation (16 studies: 6.5 [Japan] to 540.0 [Turkey]). Only 3 axSpA and no nr-axSpA prevalence rates were reported. Considerable variation was seen in the methodology used to estimate incidence and prevalence rates, e.g. screening method, study design, and classification criteria. Although the prevalence of AS is known to vary by HLA-B27 status, only 4 studies reported this genetic marker. Conclusion There is an unmet need for future studies to use consistent methodology, capture all relevant information (including HLA-B27 positivity), and investigate under-reported populations (e.g. nr-axSpA; southern hemisphere countries) to estimate the population burden of axSpA. Future studies should aim to address data gaps to provide accurate incidence/ prevalence estimates for the global axSpA population.",
keywords = "Ankylosing spondylitis, Epidemiology, Incidence, Prevalence, Spondylarthropathies",
author = "Rhonda Bohn and Maureen Cooney and Deodhar, {Atulya (Atul)} and Curtis, {Jeffrey R.} and Amanda Golembesky",
year = "2018",
month = "1",
day = "1",
language = "English (US)",
volume = "36",
pages = "263--274",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "2",

}

TY - JOUR

T1 - Incidence and prevalence of axial spondyloarthritis

T2 - Methodologic challenges and gaps in the literature

AU - Bohn, Rhonda

AU - Cooney, Maureen

AU - Deodhar, Atulya (Atul)

AU - Curtis, Jeffrey R.

AU - Golembesky, Amanda

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective The incidence and prevalence of axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic (nr-)axSpA, have been investigated in multiple populations, though there is a paucity of population-level data. Here, we identify population-based studies in AS and nr-axSpA, and describe the methodologic challenges in conducting these, outlining potential reasons for disparate incidence and prevalence estimates. Methods PubMed and Embase were searched for population-based studies providing incidence and prevalence rates, published in English from 1 Jan 2000-30 Jun 2015. Extracted information included incidence/prevalence rates, geographical population, study design, data source, case definition, age/gender, and classification criteria used. Results Of 2,148 articles identified, 19, from 15 countries, fulfilled eligibility criteria. Incidence rates per 100,000 patient-years were reported in 4 AS studies and varied from 0.4 (Iceland) to 15.0 (Canada). Reported AS prevalence rates per 100,000 persons also showed considerable variation (16 studies: 6.5 [Japan] to 540.0 [Turkey]). Only 3 axSpA and no nr-axSpA prevalence rates were reported. Considerable variation was seen in the methodology used to estimate incidence and prevalence rates, e.g. screening method, study design, and classification criteria. Although the prevalence of AS is known to vary by HLA-B27 status, only 4 studies reported this genetic marker. Conclusion There is an unmet need for future studies to use consistent methodology, capture all relevant information (including HLA-B27 positivity), and investigate under-reported populations (e.g. nr-axSpA; southern hemisphere countries) to estimate the population burden of axSpA. Future studies should aim to address data gaps to provide accurate incidence/ prevalence estimates for the global axSpA population.

AB - Objective The incidence and prevalence of axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic (nr-)axSpA, have been investigated in multiple populations, though there is a paucity of population-level data. Here, we identify population-based studies in AS and nr-axSpA, and describe the methodologic challenges in conducting these, outlining potential reasons for disparate incidence and prevalence estimates. Methods PubMed and Embase were searched for population-based studies providing incidence and prevalence rates, published in English from 1 Jan 2000-30 Jun 2015. Extracted information included incidence/prevalence rates, geographical population, study design, data source, case definition, age/gender, and classification criteria used. Results Of 2,148 articles identified, 19, from 15 countries, fulfilled eligibility criteria. Incidence rates per 100,000 patient-years were reported in 4 AS studies and varied from 0.4 (Iceland) to 15.0 (Canada). Reported AS prevalence rates per 100,000 persons also showed considerable variation (16 studies: 6.5 [Japan] to 540.0 [Turkey]). Only 3 axSpA and no nr-axSpA prevalence rates were reported. Considerable variation was seen in the methodology used to estimate incidence and prevalence rates, e.g. screening method, study design, and classification criteria. Although the prevalence of AS is known to vary by HLA-B27 status, only 4 studies reported this genetic marker. Conclusion There is an unmet need for future studies to use consistent methodology, capture all relevant information (including HLA-B27 positivity), and investigate under-reported populations (e.g. nr-axSpA; southern hemisphere countries) to estimate the population burden of axSpA. Future studies should aim to address data gaps to provide accurate incidence/ prevalence estimates for the global axSpA population.

KW - Ankylosing spondylitis

KW - Epidemiology

KW - Incidence

KW - Prevalence

KW - Spondylarthropathies

UR - http://www.scopus.com/inward/record.url?scp=85045655349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045655349&partnerID=8YFLogxK

M3 - Article

C2 - 29148402

AN - SCOPUS:85045655349

VL - 36

SP - 263

EP - 274

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 2

ER -